GliaPharm
Geneva
About GliaPharm
GliaPharm is a Swiss-based biotechnology company that offers treatments for neurological and psychiatric disorders. GliaPharm's innovative therapeutic approach is to target glial cells , the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Their vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions. GliaPharm is a Swiss biotechnology company active in the development of treatments for neurological and psychiatric diseases. The innovative therapeutic approach of GliaPharm is to target glial cells , or 'support cells' of neurons, to support and improve brain metabolism under certain pathological conditions. Their vision is to become a leader in the development of glial cell targeting agents that act as neuroprotective agents and maintain cognitive functions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $6.4M
- Funding stage: Seed
- Last round: Grant (Sep 2024)
- Website: gliapharm.com
- Phone: 41 22 545 11 15
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/gliapharm-51605 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.